Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$29.4M Sell
1,047,000
-473,900
-31% -$12.6M 0.01% 882
2025
Q4
$37.9M Buy
1,520,900
+708,900
+87% +$17.9M 0.02% 754
2025
Q3
$20.7M Sell
812,000
-119,600
-13% -$2.95M 0.01% 1043
2025
Q2
$22.6M Sell
931,600
-806,800
-46% -$18.8M 0.01% 904
2025
Q1
$44.1M Buy
1,738,400
+63,300
+4% +$1.66M 0.02% 592
2024
Q4
$44.4M Buy
1,675,100
+214,100
+15% +$5.81M 0.03% 570
2024
Q3
$42.3M Buy
1,461,000
+367,500
+34% +$10.7M 0.02% 608
2024
Q2
$30.6M Sell
1,093,500
-107,400
-9% -$2.96M 0.02% 705
2024
Q1
$33.3M Sell
1,200,900
-419,500
-26% -$11.6M 0.02% 658
2023
Q4
$46.7M Buy
1,620,400
+901,900
+126% +$27.3M 0.03% 487
2023
Q3
$23.8M Sell
718,500
-504,300
-41% -$17.8M 0.02% 703
2023
Q2
$44.9M Sell
1,222,800
-1,984,800
-62% -$77.3M 0.03% 480
2023
Q1
$131M Buy
3,207,600
+1,798,000
+128% +$77.7M 0.09% 175
2022
Q4
$72.2M Buy
1,409,600
+744,000
+112% +$35.7M 0.06% 306
2022
Q3
$29.1M Sell
665,600
-186,800
-22% -$9.08M 0.02% 602
2022
Q2
$44.7M Buy
852,400
+360,700
+73% +$18.4M 0.03% 417
2022
Q1
$25.5M Sell
491,700
-1,549,400
-76% -$80.4M 0.02% 818
2021
Q4
$121M Buy
2,041,100
+753,100
+58% +$37.3M 0.06% 268
2021
Q3
$55.4M Buy
1,288,000
+649,800
+102% +$28.8M 0.03% 484
2021
Q2
$25M Sell
638,200
-220,500
-26% -$8.57M 0.02% 878
2021
Q1
$31.1M Sell
858,700
-1,523,900
-64% -$54.1M 0.02% 709
2020
Q4
$87.7M Sell
2,382,600
-414,084
-15% -$15.2M 0.05% 314
2020
Q3
$97.4M Buy
2,796,684
+1,109,019
+66% +$38.9M 0.06% 249
2020
Q2
$52.4M Sell
1,687,665
-434,986
-20% -$14.8M 0.04% 381
2020
Q1
$65.7M Buy
2,122,651
+615,536
+41% +$21M 0.06% 277
2019
Q4
$56M Buy
1,507,115
+423,392
+39% +$15.1M 0.04% 454
2019
Q3
$36.9M Buy
1,083,723
+288,480
+36% +$10.5M 0.03% 581
2019
Q2
$32.7M Sell
795,243
-728,525
-48% -$28.9M 0.03% 640
2019
Q1
$61.4M Sell
1,523,768
-1,135,263
-43% -$45.5M 0.06% 325
2018
Q4
$110M Buy
2,659,031
+526,789
+25% +$21.9M 0.11% 164
2018
Q3
$89.2M Sell
2,132,242
-1,183,115
-36% -$45.5M 0.08% 216
2018
Q2
$114M Buy
3,315,357
+2,702,140
+441% +$92.3M 0.1% 155
2018
Q1
$20.6M Sell
613,217
-1,297,790
-68% -$44.6M 0.02% 761
2017
Q4
$65.7M Sell
1,911,007
-191,618
-9% -$6.53M 0.05% 342
2017
Q3
$71.2M Sell
2,102,625
-41,843
-2% -$1.34M 0.06% 285
2017
Q2
$68.3M Sell
2,144,468
-18,368,796
-90% -$579M 0.06% 252
2017
Q1
$666M Buy
20,513,264
+17,813,232
+660% +$562M 0.59% 12
2016
Q4
$83.2M Sell
2,700,032
-49,538
-2% -$1.51M 0.08% 251
2016
Q3
$88.4M Buy
2,749,570
+141,658
+5% +$4.74M 0.08% 216
2016
Q2
$87.1M Sell
2,607,912
-2,323,438
-47% -$74.2M 0.09% 208
2016
Q1
$139M Buy
4,931,350
+322,208
+7% +$9.2M 0.16% 101
2015
Q4
$141M Sell
4,609,142
-4,103,960
-47% -$129M 0.14% 119
2015
Q3
$260M Buy
8,713,102
+5,582,617
+178% +$179M 0.24% 46
2015
Q2
$99.6M Buy
3,130,485
+1,923,550
+159% +$62.7M 0.09% 204
2015
Q1
$39.8M Sell
1,206,935
-1,555,704
-56% -$49.5M 0.04% 438
2014
Q4
$81.6M Buy
2,762,639
+54,491
+2% +$1.56M 0.07% 270
2014
Q3
$76M Sell
2,708,148
-161,683
-6% -$4.54M 0.07% 263
2014
Q2
$80.8M Buy
2,869,831
+1,516,390
+112% +$43.2M 0.08% 244
2014
Q1
$41.2M Sell
1,353,441
-1,746,162
-56% -$52.1M 0.04% 397
2013
Q4
$90.1M Buy
3,099,603
+92,857
+3% +$2.7M 0.08% 221
2013
Q3
$81.9M Sell
3,006,746
-1,555,282
-34% -$42.3M 0.08% 234
2013
Q2
$121M Buy
+4,562,028
New +$126M 0.12% 117

Other funds holding PFE

Citigroup's PFE Position: Q1 2026 in Review

Citigroup increased its Pfizer (PFE) stake by 8.6% in Q1 2026, buying an estimated $32.7M and bringing the position to 15,493,259 shares worth $435M. The position accounts for 0.19% of the portfolio, ranked #98.

Citigroup first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Citigroup held 15,493,259 shares of Pfizer worth $435M as of Q1 2026.
  • Citigroup bought 1,228,140 Pfizer shares in Q1 2026, an estimated $32.7M.
  • Pfizer made up 0.19% of Citigroup's portfolio in Q1 2026, its #98 holding.
  • Citigroup first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.